Transgene, a biotechnology company designing and developing viral vector-based immunotherapies against cancers, and NEC Corporation, a leader in information technology, networking and artificial intelligence (AI), announce the presentation of new data on TG4050, an individualized neoantigen vaccine at the American Society of Clinical Oncology Annual Meeting (ASCO 2023) in Chicago (USA).

TG4050 is based on Transgene's myvac ® platform and benefits from NEC's Artificial Intelligence (AI) technologies.

The new positive data were generated in HPV-negative head and neck cancer patients treated in a Phase I trial currently evaluating TG4050 (NCT04183166). All patients treated with TG4050 in this trial developed a specific immune response, as demonstrated by the results of further immunological analyses, and remain in remission to this day.

Alessandro Riva, Chairman and CEO of Transgene, commented: ' TG4050 is demonstrating its potential to prolong remission in patients after surgery, positioning Transgene as a pioneer in the emerging field of individualized cancer vaccines. The single-agent data we are presenting at ASCO provide a solid basis to accelerate the clinical development of this innovative therapy as an adjuvant treatment for HPV-negative head and neck carcinoma and potentially in other indications. '

Copyright (c) 2023 CercleFinance.com. All rights reserved.